Actively Recruiting
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Led by Aldeyra Therapeutics, Inc. · Updated on 2026-02-11
20
Participants Needed
1
Research Sites
43 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
CONDITIONS
Official Title
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 21 years old or older
- Biopsy-proven primary vitreoretinal lymphoma
- Presence of lymphomatous vitreous cells at screening or confirmation via vitrectomy
- Willing to participate and provide informed consent
You will not qualify if you...
- Allergy or hypersensitivity to methotrexate
- Planned eye surgery during the trial
- Pregnant or lactating women of childbearing potential
- Pre-existing ocular or systemic conditions interfering with trial conduct
- Use of systemic methotrexate within one week prior to treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bascom Palmer Eye Institute
Miami, Florida, United States, 33101
Actively Recruiting
Research Team
B
Bill Cavanagh
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here